CNS Pharmaceuticals, Inc.
CNSPDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Berubicin | Phase 2 | Glioblastoma Multiforme, Adult | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in CNS Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in CNS Pharmaceuticals, Inc.'s (CNSP) pipeline across Phase 2. Its lead program is Berubicin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CNS Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for CNS Pharmaceuticals, Inc. (CNSP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CNSP biotech catalysts?→
Add CNSP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CNS Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.